Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Melanoma 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Merkel Cell 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Thymoma 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Microsatellite Instability 1Mesothelioma 1

Interventions

pembrolizumab 44Carboplatin 17Pemetrexed 14Paclitaxel 13Cisplatin 13lenvatinib 5Etoposide 5Docetaxel 5epacadostat 4Gemcitabine 4Albumin-Bound Paclitaxel 4durvalumab 3Nivolumab 3130-nm albumin-bound paclitaxel 3spartalizumab 2olaparib 2Saline Solution 2Immune Checkpoint Inhibitors 2Dexamethasone 2Acetaminophen 2sacituzumab govitecan 1ribociclib 1patritumab deruxtecan 1osimertinib 1etoposide phosphate 1efineptakin alfa 1cemiplimab 1camrelizumab 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × avelumab × Thoracic × Clear all
NCT03076554 2026-05-29

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
56 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡